US OptionsDetailed Quotes

LYEL250117C500

Watchlist

0.00
0.000.00%

15min DelayClose Jan 7 09:30 ET

0.00High0.00Low

Lyell Immunopharma Stock Discussion

Teddy123

Dec 10, 2024 03:06

Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting

$Lyell Immunopharma (LYEL.US)$
Lyell's IMPT-314 Cancer Therapy Shows Stunning 94% Response Rate in Lymphoma Trial

Wins333

Nov 20, 2024 14:11

$Lyell Immunopharma (LYEL.US)$ what a day

Teddy123

Nov 8, 2024 05:40

Lyell Immunopharma Reports Business Highlights and Financial Results for the Third Quarter 2024

$Lyell Immunopharma (LYEL.US)$
Acquired ImmPACT Bio and strengthened clinical pipeline with the addition of IMPT-314, a dual-targeting CD19/CD20 CAR T-cell product candidate with strong Phase 1 clinical data in patients with aggressive relapsed/refractory B-cell non-Hodgkin’s lymphoma
Presenting initial data from Phase 1 multi-center clinical trial of IMPT-314 at the American Society of Hematology 2024...

Teddy123

Nov 7, 2024 07:15

When will u start moving

$Lyell Immunopharma (LYEL.US)$

Teddy123

Nov 5, 2024 08:39

Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting

$Lyell Immunopharma (LYEL.US)$
05/11/2024 - 22:30
SOUTH SAN FRANCISCO, Calif., Nov. 05, 2024 (GLOBE NEWSWIRE) -- Lyell Immunopharma, Inc. (Nasdaq: LYEL), a clinical-stage company advancing a pipeline of next-generation CAR T-cell therapies for patients with solid tumors or hematologic malignancies, ...